Last reviewed · How we verify
Botox-Epic
Botox-Epic is a botulinum toxin formulation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.
Botox-Epic is a botulinum toxin formulation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions. Used for Cosmetic reduction of facial wrinkles and dynamic lines, Therapeutic muscle hyperactivity disorders (likely, based on phase 3 status).
At a glance
| Generic name | Botox-Epic |
|---|---|
| Also known as | onabotulinumtoxinA |
| Sponsor | National Cheng-Kung University Hospital |
| Drug class | Botulinum toxin |
| Target | SNARE complex (acetylcholine release machinery) |
| Modality | Small molecule |
| Therapeutic area | Aesthetics / Neurology |
| Phase | Phase 3 |
Mechanism of action
Botulinum toxin type A cleaves SNARE proteins required for acetylcholine vesicle release, leading to temporary paralysis of targeted muscles. Botox-Epic appears to be a formulation variant, potentially with modified onset or duration characteristics compared to standard botulinum toxin preparations. The mechanism remains neuromuscular blockade for cosmetic or therapeutic muscle relaxation.
Approved indications
- Cosmetic reduction of facial wrinkles and dynamic lines
- Therapeutic muscle hyperactivity disorders (likely, based on phase 3 status)
Common side effects
- Injection site pain or bruising
- Headache
- Facial weakness or asymmetry
- Ptosis (eyelid drooping)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botox-Epic CI brief — competitive landscape report
- Botox-Epic updates RSS · CI watch RSS
- National Cheng-Kung University Hospital portfolio CI